News Blow for AstraZeneca as cancer combination fails After several years of growing expectation, AstraZeneca’s long-awaited MYSTIC immune-oncology trial has failed to show benefit over standard lung cancer therapy.
News Soriot commits to AstraZeneca as shares slide AstraZeneca (AZ) has tried to put a brave face on today’s news that its immunotherapy combination is unlikely to be a contender in lung cancer.
News Bayer trial combines two top drugs for kidney disease Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.